Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: Long-term kidney allograft survival remains limited by immune and nonimmune injury, while conventional surveillance tools are constrained by delayed detection, limited specificity, or invasiveness. Urine provides an accessible window into the allograft, containing inflammatory mediators, cells, extracellular vesicles, nucleic acids, proteins, peptides, and metabolites reflecting intra-graft processes. RECENT FINDINGS: Over the past two decades, urinary biomarkers have evolved from single-analyte discovery to molecular signatures matched to kidney biopsy findings. Urinary CXCL9/CXCL10, urinary-cell mRNA, extracellular-vesicle transcriptomics, donor-derived cell-free DNA, proteomics, and metabolomics provide complementary measures of allograft injury and have demonstrated encouraging diagnostic performance. Although some remain limited by variable specificity, analytical standardization, reproducibility, or insufficient prospective validation, others have undergone multicenter validation, assay standardization, and progression toward clinical implementation. SUMMARY: Urinary biomarkers are unlikely to replace biopsy with a single universal test. Their greatest potential lies in context-specific applications, including risk stratification, surveillance, biopsy triage, differential diagnosis, prognostication, and treatment-response monitoring. High negative predictive value across several platforms may support reducing unnecessary biopsies. Clinical translation will depend on standardized, transferable assays, external validation in representative populations, clearly defined contexts of use, and evidence that biomarker-guided strategies improve patient and allograft outcomes.
No takes yet. Share an insight, caveat, or question.
Fekih et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: